Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Wendys Co — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Wendys Co trades at $6.46 (market cap $1.23B). The key difference: Wendys Co is the larger of the two by market cap, and Wendys Co pays a 4.35% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Wendys Co for 78 Days on average.
| MRVI | WEN | |
|---|---|---|
Market Cap | $977.37M | $1.23B |
Volume | 2,742,564 | 6,130,931 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $9.33 |
52-Week Low | $2.83 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $1.08B | $4.96B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Wendy's (WEN) trades at $6.35, up 0.63% with a bearish technical outlook. The stock shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, but faces fundamental challenges including declining net income margins (5.72% in 2026) and high debt levels. Recent news highlights franchisee bankruptcies and competitive pressures, though the company has beaten earnings expectations for three consecutive quarters. Analyst consensus remains cautious with a $7.58 price target and 64.71% hold rating.
The investment case balances deep value against operational headwinds. While valuation appears compelling, declining profitability, franchisee instability, and intense competition create significant risks. The stock offers a dividend yield but requires successful execution under new leadership to reverse negative trends. Near-term catalysts include Q3 2026 earnings and management's turnaround strategy implementation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
